Marijean Buhse
Stony Brook University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marijean Buhse.
International journal of MS care | 2014
Marijean Buhse; Wendy M. Banker; Lynn M. Clement
BACKGROUND This study was conducted to determine which factors (clinical and demographic) are associated with mental and physical health-related quality of life (HRQOL) among people with multiple sclerosis (MS) aged 60 years and older. METHODS Data were collected at four MS centers on Long Island, New York, from a total of 211 patients. Three surveys were administered that collected demographic information and included validated questionnaires measuring quality of life (QOL), cognition, depression, and disability. Multivariate linear regression analyses examined the relationship between patient demographics and scores on standardized scales measuring mental and physical HRQOL (Multiple Sclerosis Quality of Life-54). Variables included in the regression models were selected on the basis of the Andersen Healthcare Utilization model. This framework encompasses the multiple influences on health status, including predisposing characteristics, enabling resources, need, and health behavior. RESULTS We found that mental HRQOL was negatively associated with having a high school education or less, risk of neurologic impairment, physical disability, and depression. No variables were positively associated with mental HRQOL. Physical HRQOL was negatively associated with risk of neurologic impairment, physical disability, depression, and the comorbidity of thyroid disease. However, patient employment and, surprisingly, being widowed were positively associated with physical HRQOL. These findings are consistent with those of similar studies among younger patients in which lower HRQOL was associated with increased disability, depression, risk of neurologic impairment, and lower levels of education. CONCLUSIONS The findings that patient employment and being widowed were associated with better physical HRQOL suggest that older patients have the ability to adapt and adjust to the challenges of MS over time. Clinicians should regularly screen for HRQOL in older patients with MS.
Multiple Sclerosis Journal | 2018
Daniel Golan; Glen M. Doniger; Karl Wissemann; Myassar Zarif; Barbara Bumstead; Marijean Buhse; Lori Fafard; Idit Lavi; Jeffrey Wilken; Mark Gudesblatt
Background: The association between subjective cognitive fatigue and objective cognitive dysfunction in patients with multiple sclerosis (PwMS) has been studied, with conflicting results. Objective: To explore the impact of fatigue on cognitive function, while controlling for the influence of depression, disability, comorbidities, and psychotropic medications. Methods: PwMS completed a computerized cognitive testing battery with age- and education-adjusted cognitive domain scores. Disability (Expanded Disability Status Scale (EDSS)), cognitive fatigue, and depression were concurrently evaluated. Results: In all, 699 PwMS were included. Both cognitive fatigue and depression were significantly and negatively correlated with the same cognitive domains: information processing speed, executive function, attention, motor function, and memory (−0.15 ⩽ r ⩽ −0.14 for cognitive fatigue; −0.24 ⩽ r ⩽ −0.19 for depression). Multivariate analysis revealed significant but small independent correlations only between depression and neuropsychological test results, while cognitive fatigue had no independent correlation with objective cognitive function except for a trend toward impaired motor function in highly fatigued PwMS. Depression and cognitive fatigue accounted for no more than 6% of the variance in objective cognitive domain scores. Conclusion: Cognitive fatigue is not independently related to objective cognitive impairment. Depression may influence cognitive function of PwMS primarily when it is severe. Cognitive impairment in PwMS should not be ascribed to fatigue or mild depression.
Neurology | 2015
Mark Gudesblatt; Myassar Zarif; Barbara Bumstead; Marijean Buhse; Lori Fafard; Daniel Golan; Cynthia Sullivan; Jeffrey Wilken; Glen M. Doniger
Neurology | 2018
Daniel Golan; Mark Gudesblatt; Karl Wissemann; Myassar Zarif; Barbara Bumstead; Lori Fafard; Cynthia Sullivan; Jeffrey Wilken; Karen Blitz-Shabbir; Marijean Buhse; Glen M. Doniger
Neurology | 2018
Zohra Hamid; Mark Gudesblatt; Justin Underwood; Karl Wissemann; Lori Fafard; Jared Srinivasan; Barbara Bumstead; Marijean Buhse; Myassar Zarif; Karen Blitz-Shabbir
Neurology | 2018
Mark Gudesblatt; Stacy Trebing; Christina Burke; Karl Wissemann; Myassar Zarif; Barbara Bumstead; Lori Fafard; Marijean Buhse; Karen Blitz-Shabbir
CNS Drugs | 2018
Mark Gudesblatt; Karl Wissemann; Myassar Zarif; Barbara Bumstead; Lori Fafard; Jeffrey Wilken; Karen Blitz; Marijean Buhse; Sourav Santra; Christophe Hotermans; Lily Lee
Neurology | 2016
Myassar Zarif; Karl Wissemann; Peter Marcote; Barbara Bumstead; Christina Burke; Lori Fafard; Smitha Thotam; Marijean Buhse; Jacob J. Sosnoff; Lisa M. Muratori; Mark Gudesblatt
Neurology | 2016
Patricia Dunham; Karl Wissemann; Danielle Salomone; Marijean Buhse; Lori Fafard; Myassar Zarif; Mark Gudesblatt
Neurology | 2016
Christina Burke; Mark Gudesblatt; Karl Wissemann; Myassar Zarif; Barbara Bumstead; Lori Fafard; Smitha Thotam; John Magel; Marijean Buhse; Lisa M. Muratori
Collaboration
Dive into the Marijean Buhse's collaboration.
New York Institute of Technology College of Osteopathic Medicine
View shared research outputs